Lebwohl Mark, Langley Richard G, Paul Carle, Puíg Lluis, Reich Kristian, van de Kerkhof Peter, Wu Hsiuan-Lin, Richter Sven, Jardon Shauna, Gisondi Paolo
Department of Dermatology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1048, New York, NY, 10029, USA.
Division of Dermatology, Department of Medicine, Dalhousie University, Halifax, Canada.
Dermatol Ther (Heidelb). 2022 Jan;12(1):61-78. doi: 10.1007/s13555-021-00635-4. Epub 2021 Oct 25.
Since the 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, several systemic treatments for psoriasis (PsO) and/or psoriatic arthritis (PsA) have been approved. The population-based UPLIFT survey was conducted to understand how perceptions of treatment-related outcomes have evolved, particularly for patients with mild to moderate PsO and/or PsA and their dermatologists.
This population- and web-based survey was conducted from 2 March to 3 June 2020, in North America, Europe, and Japan. Adults with self-reported healthcare practitioner (HCP)-diagnosed PsO and/or PsA and dermatologists who spent > 50% of time treating patients and treated ≥ 20 patients with PsO, including plaque PsO, per month were included. Patient participants were recruited at random from online panels; dermatologists were recruited randomly from representative physician panels.
Of 264,054 patient responses, 3806 who self-reported an HCP diagnosis of PsO and/or PsA were included in the final sample; 67% had PsO alone, 28% had PsO and PsA, and 5% had PsA alone. The estimated population prevalence of psoriatic disease was 7% (PsO only: 4%; PsO and PsA: 2%; PsA only: 1%). Most patients (78%) reported PsO-involved body surface area (BSA) ≤ 3 palms, and ~ 90% or more reported itching, redness, flaking, and scales. Many PsO patients without diagnosed PsA reported musculoskeletal symptoms suggestive of PsA (63%). Across BSA categories, approximately one in four patients was not currently receiving treatment and > 50% had Dermatology Life Quality Index score > 5. Patients and dermatologists had different perceptions of PsO severity, office visit discussions, treatment goals, and treatment satisfaction. The survey was conducted during the coronavirus disease 2019 (COVID-19) pandemic, which could have affected assessments of patient-reported outcomes and ability to have in-person HCP visits.
Patients with PsO and PsA in UPLIFT reported high disease burden, including patients with limited skin involvement. An opportunity exists to align patient and dermatologist perceptions to optimize management of PsO and PsA.
DIGITAL FEATURE: This article is published with digital features, including an infographic, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.17104586 .
自2012年银屑病和银屑病关节炎多国评估（MAPP）调查以来，已有几种用于治疗银屑病（PsO）和/或银屑病关节炎（PsA）的系统疗法获得批准。开展了基于人群的UPLIFT调查，以了解对治疗相关结局的认知是如何演变的，尤其是对于轻度至中度PsO和/或PsA患者及其皮肤科医生。
这项基于人群和网络的调查于2020年3月2日至6月3日在北美、欧洲和日本进行。纳入了自我报告有医疗保健从业者（HCP）诊断为PsO和/或PsA的成年人，以及每月花费超过50%时间治疗患者且治疗≥20例PsO患者（包括斑块状PsO）的皮肤科医生。患者参与者从在线小组中随机招募；皮肤科医生从代表性医师小组中随机招募。
在264,054份患者回复中，最终样本纳入了3806名自我报告有HCP诊断为PsO和/或PsA的患者；67%仅患有PsO，28%患有PsO和PsA，5%仅患有PsA。银屑病疾病的估计人群患病率为7%（仅PsO：4%；PsO和PsA：2%；仅PsA：1%）。大多数患者（78%）报告PsO累及的体表面积（BSA）≤3个手掌大小，约90%或更多的患者报告有瘙痒、发红、脱屑和鳞屑。许多未诊断为PsA的PsO患者报告有提示PsA的肌肉骨骼症状（63%）。在不同BSA类别中，约四分之一的患者目前未接受治疗，超过50%的患者皮肤病生活质量指数评分>5。患者和皮肤科医生对PsO严重程度、门诊讨论、治疗目标和治疗满意度的认知存在差异。该调查是在2019冠状病毒病（COVID-19）大流行期间进行的，这可能影响了对患者报告结局的评估以及进行面对面HCP就诊的能力。
UPLIFT调查中的PsO和PsA患者报告了较高的疾病负担，包括皮肤受累有限的患者。存在使患者和皮肤科医生的认知达成一致以优化PsO和PsA管理的机会。
数字特色：本文发表时带有数字特色，包括信息图，以促进对本文的理解。要查看本文的数字特色，请访问https://doi.org/10.6084/m9.figshare.17104586 。
